Compare Docusign Inc (DOCU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs BIO-TECHNE Corp — how do they compare? Docusign Inc trades at $71 (market cap $12.88B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Docusign Inc and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Docusign Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and BIO-TECHNE Corp for 63 Days on average.
| DOCU | TECH | |
|---|---|---|
Market Cap | $12.88B | $11.37B |
Volume | 2,591,969 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $73.14 | $72.61 |
52-Week Low | $41.75 | $43.31 |
Typical Hold Time | 71 Days | 63 Days |
Enterprise Value | $12.28B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $71.43, up 4.71% with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. The company shows robust revenue growth reaching $2.98B in 2025 with improving profit margins, though valuation ratios remain elevated. Recent news highlights AI integration in contract processing and leadership recognition in workflow software.
Outlook remains positive with projected revenue growth to $3.4B in 2026, supported by AI adoption and operating leverage. Risks include insider selling, competitive pressures, and high valuation multiples. Analyst consensus is cautious with 64% hold ratings, but technical strength and fundamental improvements suggest potential for continued upside if execution persists.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
